Profound Medical (NASDAQ:PROF) Posts Earnings Results

Profound Medical (NASDAQ:PROF - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.11, Zacks reports. The firm had revenue of $4.18 million for the quarter, compared to the consensus estimate of $5.92 million. Profound Medical had a negative return on equity of 85.22% and a negative net margin of 349.41%.

Profound Medical Price Performance

Shares of PROF traded down $0.12 during trading hours on Monday, reaching $6.74. 86,317 shares of the stock traded hands, compared to its average volume of 76,076. The company has a current ratio of 6.12, a quick ratio of 5.16 and a debt-to-equity ratio of 0.11. Profound Medical has a 52-week low of $5.63 and a 52-week high of $11.42. The company's 50-day moving average price is $7.02 and its two-hundred day moving average price is $7.57. The company has a market cap of $202.47 million, a P/E ratio of -5.03 and a beta of 0.78.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.